Hansoh Pharmaceutical Group logo

Hansoh Pharmaceutical Group(SEHK) 3692

Market CapHK$202.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+83%
5 Year+69%
1 Year-5%
1 Month-9%
HK$33.52
+0.36%
+0.12Today
Hansoh Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 33.522026-09-29
Hansoh Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.15%HKD 35.342026-09-22
1 month-8.71%HKD 36.722026-08-28
3 month+13.17%HKD 29.622026-06-30
Year to date-7.1%HKD 36.082025-12-31
1 year-5.42%HKD 35.442025-09-29
3 year+214.45%HKD 10.662023-09-29
5 year+69.29%HKD 19.802021-09-30
Since inception+83.26%HKD 18.232019-06-14

Hansoh Pharmaceutical Group Financials at a Glance

Market Cap

HK$202.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥29.09B

Net Income (TTM)

CN¥11.46B

EPS (TTM)

HK$1.24

P/E Ratio

26.86

Dividend

HK$0.49

Beta (Volatility)

-0.04 (Low)

Price

HK$33.52

Volume

12,097,563

Open

HK$33.40

Previous Close

HK$33.40

Daily Range

HK$33.16 - HK$33.98

52-Week Range

HK$28.06 - HK$44.22

Estimated Earnings Date

Mar 30, 2027

3692 News

Pharmacists reviewing medication

5 Best GLP-1 Stocks for 2026 and How to Invest

Rachel WarrenSep 22, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hansoh Pharmaceutical Group

Hansoh Pharmaceutical Group Company Limited is a leading pharmaceutical company based in China, specializing in the research, development, production, and sale of innovative drugs. The company focuses on therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases, aiming to improve patient outcomes through advanced medical solutions.

Products and Services
  • Offers a diverse range of pharmaceutical products for various therapeutic areas
  • Key products include Ameile, Hansoh Xinfu, and Zefei
  • Engages in strategic partnerships for drug development with global pharmaceutical companies
Growth Outlook
  • Revenue for Q2 2026 reached CNY 8.30 billion, showing strong demand
  • Net income margin of 51.3% indicates effective cost management
  • Continued investment in R&D, with CNY 1.72 billion allocated in Q2 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 30.67 billion reflects consistent growth
  • Operating income margin of 44.6% demonstrates operational efficiency
  • Current ratio of 4.88 indicates strong liquidity position
Hansoh Pharmaceutical Group Company Limited has established itself as a significant player in the pharmaceutical industry, particularly within China. The company's commitment to research and development is evident in its substantial investment, which supports the ongoing innovation of its product offerings. The recent financial performance highlights a robust revenue stream and strong profitability, positioning the company favorably for future growth. With a diverse product portfolio and strategic partnerships, Hansoh is well-equipped to navigate the evolving healthcare landscape and meet the increasing demand for effective pharmaceutical solutions.
AI Generated • Sep 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,347

CEO

Hui Juan Zhong, EMBA

Website

www.hspharm.com

Headquarters

Shanghai, SH 201210, CN

3692 Financials

Key Financial Metrics (TTM)

Gross Margin

90.47%

Operating Margin

37.52%

Net Income Margin

42.01%

Return on Equity

18.26%

Return on Capital

15.26%

Return on Assets

14.33%

Earnings Yield

3.72%

Dividend Yield

1.45%

Payout Ratio

30.13%

Stock Overview

Market Cap

HK$202.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.06B

Volume

12.10M

Avg. Volume

11.91M

Financials (TTM)

Gross Profit

CN¥26.36B

Operating Income

CN¥10.42B

EBITDA

CN¥11.08B

Operating Cash Flow

CN¥11.97B

Capital Expenditure

-CN¥740.35M

Free Cash Flow

CN¥11.22B

Cash & ST Invst.

CN¥37.38B

Total Debt

CN¥4.23B

Hansoh Pharmaceutical Group Performance Analysis

Hansoh Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 10,910,600,033-8.9%
20232023-12-31CNY 11,164,685,3942.3%
20242024-12-31CNY 13,293,466,86719.1%
20252025-12-31CNY 16,298,568,60122.6%
Hansoh Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-11.5%
Q22025-06-3029.2%
Q42025-12-312.2%
Q22026-06-309.3%
Hansoh Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.51-5.0%
20232023-12-31CNY 0.6018.7%
20242024-12-31CNY 0.8032.4%
20252025-12-31CNY 1.0126.5%
Hansoh Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-39.1%
Q22025-06-3089.3%
Q42025-12-31-24.5%
Q22026-06-3072.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥8.30B

+27.6%

Gross Profit

CN¥7.63B

+28.9%

Gross Margin

91.89%

N/A

Market Cap

HK$202.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$21.00M

N/A

Employees

9,643

N/A

Net Income

CN¥4.26B

+56.2%

EBITDA

CN¥3.87B

+38.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥37.38B

+59.1%

Total Debt

CN¥4.23B

+3437.0%

Accounts Receivable

CN¥3.16B

+7.4%

Inventory

CN¥685.90M

+14.4%

Long Term Debt

CN¥134.34M

+109.5%

Short Term Debt

CN¥4.11B

+7305.8%

Return on Assets

14.33%

N/A

Return on Invested Capital

15.65%

N/A

Free Cash Flow

CN¥2.28B

-11.6%

Operating Cash Flow

CN¥2.53B

-5.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,667.21-0.00%
^DJIDJI
$51,269.71-0.00%
^IXICNASDAQ
$26,778.84-0.00%
BTCBitcoin
$83,403.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$77.36-0.23%
NVDANvidia
$227.21-0.72%
INTCIntel
$115.93-0.09%
SPCXSpace Exploration Technologies
$149.24+2.59%

Questions About 3692

What is the current price of Hansoh Pharmaceutical Group?

Hansoh Pharmaceutical Group is trading at HK$33.52 per share.

What is the 52-week range for Hansoh Pharmaceutical Group?

Over the past 52 weeks, Hansoh Pharmaceutical Group has traded between HK$28.06 and HK$44.22.

How much debt does Hansoh Pharmaceutical Group have?

As of the most recent reporting period, Hansoh Pharmaceutical Group reported total debt of CN¥117.05M.

How much cash does Hansoh Pharmaceutical Group have on hand?

Hansoh Pharmaceutical Group reported CN¥3.80B in cash and cash equivalents in its most recent financial results.

What is Hansoh Pharmaceutical Group’s dividend yield?

Hansoh Pharmaceutical Group currently has a dividend yield of 1.45%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services